Poster December 2023
Neurofi lament light chain level change in plasma of ALS patients following IPL 344 treatment in phase 1/2a clinical trial (NCT03652805, NCT03755167)
15 December 2023
Journal of Clinical Neurology and Neurosurgery
Peptide IPL344, an AKT activator, treats SOD1 ALS model mice to improve neuromuscular function
24 February 2023
Poster February 2023
Treatment with IPL344, an Akt activator, improves neuro-muscular function in SOD1G93A ALS model mice
15 February 2023
Muscle & Nerve
Proceedings of the 21st Annual Meeting of the Northeast ALS Consortium
15 November 2022
Poster November 2022
First in human phase 1/2a open label study evaluating the safety and efficacy of the Akt activator, IPL344 in amyotrophic lateral sclerosis
15 November 2022
Immunology 2017
Activation of the Akt–CREB signalling axis by a proline-rich heptapeptide confers resistance to stress-induced cell death and inflammation
15 December 2017